KR101407659B1 - A composition for inhibiting testosterone 5-alpha reductase - Google Patents

Abstract

The present invention relates to a testosterone 5-alpha reductase inhibitor comprising at least one member selected from the group consisting of horseradish extract, magpie extract, acid mulberry extract, saphenous extract, lotus extract, ≪ / RTI > The present invention also provides a pharmaceutical composition for treating or preventing a male hormone-dependent disease comprising at least one member selected from the group consisting of horseradish extract, corn oil extract, mulberry extract, corn oil extract, . The male hormone-dependent disease may be any one selected from the group consisting of alopecia, acne, seborrheic dermatitis, and enlarged prostate.
The present invention also relates to a cosmetic composition for improving or preventing hair loss, acne or seborrheic dermatitis comprising at least one member selected from the group consisting of horseradish extract, mahwang extract, mulberry extract, .

Description

A COMPOSITION FOR INHIBITING TESTOSTERONE 5-ALPHA REDUCTASE < RTI ID = 0.0 >

The present invention relates to a composition for inhibiting testosterone 5-alpha reductase, a composition for inhibiting testosterone 5-alpha reductase, a composition for treating or preventing alopecia, a composition for treating or preventing acne and seborrheic dermatitis, To a composition for treating or preventing prostatic hyperplasia.

Testosterone is a male hormone involved in male transcriptional expression, skeletal muscle increase, spermatogenesis, etc. Dehydrotestosterone (DHT), in which the testosterone is converted by a reductase, causes acne, sebum increase, And hypertrophy. That is, the testosterone-converted dihydrotestosterone is a hormone associated with hair loss, acne, and enlargement of the prostate. It is known that the production of the dihydrotestosterone is associated with male pattern hair loss, acne or enlargement of the prostate gland.

Specifically, the dihydrotestosterone is known to be one of the major inducers of male alopecia due to inhibition of cell proliferation of hair cells and induction of protein that causes hair loss, resulting in lowering of energy production and inhibition of protein synthesis around hair follicles.

In addition, recent studies have revealed that the above-mentioned dihydrotestosterone, which is over-secreted after puberty, causes excessive production of sebum in sebocytes, and is involved in diseases such as acne occurrence and worsening and seborrheic dermatitis.

In addition, dihydrotestosterone converted from testosterone by the testosterone 5-alpha reductase in the prostate affects the development and hypertrophy of the prostate, and excessive dihydrotestosterone production leads to enlargement of the prostate . In fact, dihydrotestosterone content is known to be significantly higher in tissues of patients with benign prostatic hyperplasia than in normal prostate tissues.

The testosterone 5-alpha reductase is a biocatalyst that is involved in the conversion of testosterone, which is a male hormone biosynthesized in a testis, into dihydrotestosterone, which exists mainly in the male hormone reactive tissues such as sebaceous gland, hair follicle or prostate.

Therefore, in the case of inhibiting the action of the testosterone 5-alpha reductase to produce the dihydrootestosterone to inhibit the production of dihydrootestosterone in the tissue, the treatment of the hair loss, especially male pattern hair loss, enlargement of the prostate gland or acne and seborrheic dermatitis , May be effective in preventing or improving.

Although hair loss has not been recognized as a disease in the past, hair loss in modern society, which emphasizes appearance, is one of the most important topics dealt with in modern skin science and is treated as a serious disease or cosmetic problem.

The hair of the human body is about 10,000 to 150,000, and each hair has a different parenting period, and the growth, the regenerator, and the resting period are repeatedly generated, grown and dropped. As a result, about 15% of the hair is raised in the dormant period and the retrograde period, so that an average of 50 to 100 hairs are normally dropped and regenerated on a daily basis.

In general, alopecia refers to the fact that the period corresponding to the growth period of the mother cycle is shortened due to various reasons, and the ratio of the retrograde hair to the resting hair is relatively increased, which means that the number of hair dropping is larger than the average value. The causes of alopecia are analyzed, and various theories such as the function of genetic androgen hormone, nutritional disorder due to local blood flow disorder, autonomic nervous system disorder, autoimmune disease or endocrine disorder have been suggested. In particular, research on male androgenic alopecia, which is thought to be the main cause of the double male hormone, has received much support. In this regard, it is reported that the tissue at the site of hair loss is higher in activity of testosterone 5-alpha reductase than the tissue of other scalp where hair is usually present.

It is known that the male hair loss is caused by the abnormal overgrowth of the dihydrotestosterone, which is converted into the active male hormone dihydrootestosterone by the testosterone 5-alpha reductase, the male hormone testosterone. In particular, it has been reported that dihydrootestosterone binds better to hormone receptors in several hair follicles than testosterone.

Therefore, if the activity of the testosterone 5-alpha reductase producing dihydrootestosterone is inhibited, male-type hair loss can be effectively prevented and treated.

Conventionally, minoxidil has been marketed as a drug for accelerating hair growth. Minoxidil has been used as an antihypertensive agent, and it is made of a hair growth promoter because it is adversely affected by the increase in human hair. The minoxidil is known to promote hair growth by increasing the blood flow of the scalp where the hair follicles are located. However, when minoxidil is used as a hair growth promoting agent for a long time, its effect can be reduced to half, and as a side effect due to chemical vasodilating action, asthenia and sebum increase have been reported.

Therefore, it is required to develop a substance capable of preventing or ameliorating male-pattern alopecia by inhibiting the activity of testosterone 5-alpha reductase, which produces the dihydrootestosterone from a natural substance without side effects.

In addition, the prostate is an organ that exists only in men and is a kind of hormonal organ which is located just below the bladder and surrounds the urethra. The urethra slopes diagonally to the near side of the prostate front, and the appendage tubes on both sides of the prostate pass through the parenchyma at the back of the urethra, and the prostate parenchyma is separated into three leaflets. The upper part of the appendix is referred to as the middle part, and the lower part of the upper part is called the lateral side of the urethra.

The prostate produces one third of the liquid component of male semen in the prostate, which is one of the sex-attaching organs that play a reproductive function with the testicles and seminal vesicles. The prostate solution not only nourishes sperm produced in the testicles , It prevents spermatozoa from becoming solidified and increases the motility of spermatozoa, thereby helping spermatozoa to conception. In addition, since the prostate fluid is alkaline, it neutralizes the strong acidity of the female fallopian tubes and helps the sperm reaching the fallopian tube safely and fertilize the egg.

Benign prostatic hyperplasia (BPH), one of the most common diseases associated with the prostate, is one of the most common diseases in men over the age of 50, and is associated with lower urinary tract symptoms, which decreases quality of life.

The major cause of the development of the enlarged prostate is the increase in the age and the presence of the male hormone. In particular, men with congenital testicular dysfunction or testicular clefts are not affected by enlarged prostate, suggesting that male hormones are closely involved in their induction.

Symptoms of the hypertrophy of the prostate include not being able to tolerate urine, thin and weak urine stem, hesitating for a long time, feeling urine after urination, and the like. In particular, sleeping is often performed at night because the user often feels sick.

One of the factors of the enlarged prostate is the hormone, a dihydrotestosterone converted from testosterone by the testosterone 5-alpha reductase. The dihydrotestosterone affects the development and hypertrophy of the prostate gland.

Thus, it is known that the inhibition of the testosterone 5-alpha reductase inhibits the conversion of testosterone into dihydrotestosterone, thereby reducing the size of the prostate gland, thereby exhibiting a favorable effect on the lower urinary tract symptoms.

Currently, the treatment for hypertrophic prostatitis drugs used in the treatment of hypertrophy of the prostate is largely alpha blocker and androgen inhibitor. The alpha-blocker is a drug previously used as a therapeutic agent for hypertension, and includes terazosin, doxazosin, tamsulosin or alfuzosin, and the alpha adrenergic receptor , Reducing the pressure and tension of the prostate urethra. The above-mentioned alpha-blocker is advantageous because it can be taken easily once a day, and has a high effect, but it is known to cause side effects such as dizziness, lethargy, headache, visual field abnormality.

The testosterone 5-alpha reductase inhibitor, which is the above androgen inhibitor, includes Propecia, Finestride and dutasteride. The above-mentioned androgen inhibitors are also recommended to be given only when the prostate-specific antigen (PSA) level is high and the prostate size is large due to the serious side effects such as decrease in sexual function and long time until after the administration, .

In addition, unlike female skin, the male hormone, androgen (androgen) secretion of the vigorous secretion of the sebaceous glands are increased in the secretion of sebum is about 1.5 to 2 times more than most women in the face is known have.

Acne is a chronic inflammatory disease of the sebaceous glands caused by retention hyperkeratosis, which is caused by sebum in the pores. 70% to 80% of the acne patients are concentrated in the age group of 11 to 25 years, It is one of the skin characteristics of growing period, but it is classified as skin disease in severe cases.

The causes of acne can be largely explained by the degree of development of acne symptoms due to excessive secretion of sebum, infection of pores, stenosis caused by exfoliation of hair follicles, proliferation of acne bacteria, and inflammatory reaction. The main cause of the cause of the acne is excessive sebum production. As described above, sebum is secreted from the sebaceous gland and functions to prevent the harmful substances from the outside of the skin from penetrating between the keratinocytes in the normal amount. However, If hormone balance falls under the skin, sebaceous glands are stimulated to induce excessive secretion of sebum. In particular, it is known that excessive production of dihydrotestosterone, which is a male hormone, can induce the occurrence of acne along with excessive secretion of sebum.

As described above, when the activity of testosterone 5-alpha reductase, which is a biosystem enzyme involved in the reaction of dihydrootestosterone in testosterone, is inhibited, alopecia can be treated or ameliorated. In addition to alopecia, treatment or amelioration of benign prostatic hyperplasia And can be used to treat male hormone-dependent diseases such as acne and other skin diseases. Therefore, search for new substances that inhibit the activity of testosterone 5-alpha reductase has been actively researched.

However, the inhibitor of testosterone 5-alpha reductase, which has been reported so far, is a chemical substance such as finasteride which was developed by MSD of the USA and has adverse effects such as loss of libido, decrease of ejaculatory level or erectile dysfunction, An attempt has been made to obtain the above testosterone 5-alpha reductase inhibitor from natural herbal medicines with low side effects and high safety.

KR 2007-0056207 A KR 1999-0055304 A KR 2003-0068647 A KR 2005-0030938 A KR 2007-0074690 A KR 0882780 B KR 1099664 B

 Metcalf BW et al., Trends Pharmacol Sci. 10 (12): 491-495. Review (1989)  Winson JD., J Biol Chem., 10: 250 (9): 3498-3504 (1975)  J. Invest. Dermatol. 105 (2): 209-214 (1995)

In order to meet such a demand, the present invention provides a composition for inhibiting testosterone 5-alpha reductase, which comprises as an active ingredient a plant extract having a low possibility of causing problems related to side effects .

The present invention also provides a plant extract which is not only safe from side effects but also inhibits testosterone 5-alpha reductase from natural plants which can be used for food, unlike conventional therapeutic agents, And a composition for treating or ameliorating a male hormone-dependent disease.

In order to achieve the above object, the present invention provides a testosterone 5-alpha reductase (hereinafter referred to as " testosterone 5-alpha reductase ") comprising at least one member selected from the group consisting of horseradish extract, mahwang extract, mulberry extract, testosterone 5-alpha reductase).

The present invention also provides a pharmaceutical composition for treating or preventing a male hormone-dependent disease comprising at least one member selected from the group consisting of horseradish extract, magpie extract, acid mulberry extract, saphenous extract, lotus extract, to provide.

The male hormone-dependent disease may be any one selected from the group consisting of alopecia, acne, seborrheic dermatitis, and enlarged prostate.

The present invention also provides a food composition for improving or preventing enlargement of the prostate gland, comprising at least one member selected from the group consisting of horseradish extract, corn oil extract, mulberry extract, saponin extract, extract of lotus flower and extract extract.

In addition, the present invention provides a cosmetic composition for improving or preventing hair loss comprising at least one member selected from the group consisting of horseradish extract, mahwang extract, acid mulberry extract, saphenous extract, lotus extract, and snort extract.

In addition, the present invention provides a cosmetic composition for improving or preventing acne or seborrheic dermatitis comprising at least one selected from the group consisting of horseradish extract, mahwang extract, mulberry extract, saphenous extract, lotus extract, do.

In consideration of the conventional problems, the inventors of the present invention selected intensive studies for selecting an inhibitor that can effectively inhibit testosterone 5-alpha reductase without adverse effects. As a result, Extracts, acid mulberry extracts, saponins, lotus extracts and extracts were found to inhibit testosterone 5-alpha reductase.

Furthermore, when the above extracts were used in combination, remarkable effects were obtained. In particular, in the case of Crassus L. extract, there was a remarkable increase of 68.67% when used in combination with the extract of Maquis, Especially, when mixed with mulberry extract, 98.81% of mulberry extract was remarkably effective, and the acid mulberry extract was mixed with manganese extract or softened manganese extract, preferably manganese extract. In the case of using the extract of Hornberry tree, it was remarkably effective when used in combination with the extract of Hornberry tree and softening extract. In the case of the extract of Nohwoong, the synergistic effect was not generated in the other extracts. However, Mixed with mulberry extract It was confirmed that the effect was increased.

From the above results, the present inventors have completed the present invention by confirming the optimal combination of natural plant extracts for the treatment of various diseases related to male hormone diseases by effectively inhibiting testosterone 5-alpha reductase without side effects.

Hereinafter, the present invention will be described in more detail.

In the present invention, an effective ingredient means a component that exhibits the desired activity alone or can exhibit activity together with the carrierization itself, which is not active.

In the present invention, the effective amount refers to an amount of an effective ingredient capable of exhibiting a therapeutic effect, prophylactic or preventive action of a specific activity, for example, a male hormone dependent disease, treatment, improvement or prevention of benign prostatic hyperplasia, treatment of alopecia, acne or seborrheic dermatitis .

Terms that are not specifically defined in this specification are subject to the Korean national meaning or the commonly accepted meaning in the art.

The present invention relates to a testosterone 5-alpha reductase (testosterone 5-alpha reductase) comprising at least one selected from the group consisting of plant extracts, specifically horseradish extract, -reductase inhibiting composition.

Crataegus pinnatifida is a deciduous broad-leaved arboreous tree, native to mountain regions, distributed in Korea, China and Siberia, and also known as agate. Its height is about 3 m to 6 m, the bark is ash-colored, the branches are spiny, the leaves are staggered, close to an egg shape, 6 to 8 cm in length and 5 to 6 cm in butterfly. The edges are split like feathers and the lower part is more deeply divided. There are hairs on both sided veins, irregular sawtooth on the edge, petiole is about 2 to 6 cm in length. Flowers bloom in May and hang in the flower bed of the temple, with petals round and 5 with calyx pieces. The fruit is round, white, with white spots, about 1.5 cm in diameter, ripened in reddish from September to October.

The Ephedra sinica ) is an evergreen shrub that is native to the northeastern part of China and Mongolia. Height is 30 cm to 70 cm, rootstock is yellowish red, thick woody, stem is thin and long, and there are many nodes. Flower is bloomed from July to August. It is migratory. The fruit is a berry with pink circles and two dark brown seeds in it.

The above mulberry ( Morus bombycis ) grows on the roads and roots of the nettle tree as a lead foliage tree, distributed in Korea, Japan, China, Taiwan and Sakhalin. The height is about 7 m to 8 m, and the diameter is about 50 cm. The bark is ash-toned brown. The small branches become brown with a fine hint or no hint. Leaves are ovate or broad ovate, about 8 cm to 15 cm in length, 4 to 8 cm in width, with irregular and sharp sawtooth on the edge, slightly hairs on the back vein and long end like tail. The flower is a divorced male, or male, and blooms in May. Fruits are gathered and ripened in purplish black in June, and the flesh of the flesh is combined into one fruit.

The Acer tegmentosum is a deciduous broad-leaved arboreous tree of Maplewood and is also called a mountain elm or beech. The branch was honeycomb and was named "Bee". It grows in damp valleys and valleys of high altitude of 600m above sea level, and is about 10m to 15m in height. Leaves are wide, young stems are pale green, stems are very soft and broken well, shells are thick, materials are white and light. Light yellowish-green flowers bloom, and the fruit is rhizomes and has no hairs, and ripens from September to October.

The softening ( Nelumbo Nucifera , also known as lotus, is a perennial herbaceous plant belonging to the water lily family. Its origin is India. It has been cultivated long time ago in Korea, and cultivated in rice field. The roots are long side-to-side, columnar, with many nodes, and the ends are particularly thick in autumn. The leaves come out of the rhizome and rise high on the water, close to the circle, white green, vein spreads all over and it is about 40㎝ in diameter and does not get wet. The petiole, ie, the particle lumen, is cylindrical and has a short spiny projection. The flower of the soft flower blooms in July or August and is about 15 cm to 20 cm in diameter, light pink or white, and the flower has a thorn like petiole and one flower at the end. Calyx is green, early fall, petals are 8 to 12 cm long, 3 to 7 cm wide, obovate obtuse, fruit is elliptical, length is about 2 cm and can be eaten. The softening may preferably be a softening flower, more preferably a softening flower, or softening.

Siegesbeckia glabrescens is also referred to as a wild flower of asteraceae and is known as a testicle. It is a perennial herb that grows in every part of Korea and on the roadside, and grows mainly in sunny or semi-sled. The leaves are about 40 cm to 100 cm long, the leaves are 5 cm to 13 cm long, the width is about 3.5 cm to 11 cm, irregular sawtooth on the edge, short sides on both sides, and an oval triangle. The flower is yellow and the flower is about 1 ㎝ to 3 ㎝ in length and has short hairs. It runs on the tip of the branch and the end of the main stem. The fruit runs around October and can be edible. The flotation may be any one selected from the group consisting of flotation parts of squirming, for example, squirrels, leaves and flowers.

At least one selected from the group consisting of plant extracts, specifically horseradish extract, manganese extract, acid mulberry extract, saponin extract, soft extract and squalane extract may be produced according to a conventional method for producing plant extracts, For example, by extracting a flower, leaf, branch, root, fruit or shell or crushed water of each plant with an extraction solvent or by extracting with a extraction solvent, and fractionating the crude extract with a fraction solvent.

The extraction solvent may be at least one selected from the group consisting of water and an organic solvent. The organic solvent may be a polar solvent such as an alcohol having 1 to 5 carbon atoms, a diluted alcohol such as ethyl acetate or acetone, a nonpolar solvent such as ether, chloroform, benzene, hexane or dichloromethane, or a mixture thereof. The alcohol having 1 to 5 carbon atoms may be methanol, ethanol, propanol, butanol, or isopropanol, but is not limited thereto. In addition, the alcohol dilution water may be an alcohol diluted with water at 50 to 99.9% (v / v).

The at least one extraction solvent selected from the group consisting of horseradish extract, magpie extract, acid mulberry extract, saponin extract, softener extract and squalene extract of the present invention is preferably water, an alcohol having 1 to 5 carbon atoms, And mixtures thereof. More preferably, it may be any one selected from the group consisting of water, alcohols having 1 to 4 carbon atoms, and mixtures thereof, and still more preferably 50 to 99% ethanol Aqueous solution. The extraction process may be performed, for example, at 4 ° C to 150 ° C, or 50 ° C to 120 ° C, or 80 ° C to 110 ° C, but is not limited thereto. The extraction time is not particularly limited, but may be 10 minutes to 12 hours.

One or more selected from the group consisting of plant extracts of the present invention, specifically, horseradish extract, manganese extract, acid mulberry extract, sunflower seed extract, softened extract and squalane extract may be produced by a conventional method for producing plant extracts Specifically, a cold extraction extraction method, a warm extraction extraction method, a heat extraction method, an ultrasonic extraction method and the like, and a conventional extraction device, an ultrasonic pulverization extractor or a fractionator may be used.

Further, the extract extracted with the solvent may be further fractionated with any one solvent selected from the group consisting of hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, water, and mixtures thereof. Two or more kinds of solvents may be used for the fractionation, and the solvent extracts may be sequentially used or mixed according to the polarity of the solvent.

The thus-prepared extract or the fraction obtained by performing the fractionation process may be filtered, concentrated or dried to remove the solvent, and may be subjected to both filtration, concentration and drying. Specifically, the filtration can be performed using a filter paper or a vacuum filter, and the concentration can be reduced by using a vacuum concentrator, for example, a rotary evaporator. The drying can be performed by, for example, freeze drying.

The amount of the plant extract contained in the testosterone 5-alpha reductase inhibiting composition may be 0.001 to 50% by weight, preferably 0.1 to 30% by weight based on the total weight of the composition. However, the testosterone 5-alpha reductase inhibitor The content of the active ingredient can be appropriately controlled depending on the method of use and the intended use of the composition.

The composition for inhibiting testosterone 5-alpha reductase of the present invention may contain carbohydrates, proteins, lipids, vitamins and minerals in addition to the above plant extracts. The saccharide may be selected from the group consisting of honey, dextrin, sucrose, palatinose, glucose, fructose, starch syrup, sugar alcohol, , Sorbitol, xylitol and maltitol. The protein may be milk-derived proteins such as casein, whey protein, soybean protein, animal-derived enzymes such as trypsin and pepsin of these proteins, and neutrase The lipid may be a first saturated fatty acid, a sunflower oil containing a polyunsaturated fatty acid, a rapeseed oil, an olive oil, a safflower oil, a corn oil, Derived fat such as soybean oil, palm oil and palm oil, middle-chain fatty acid, EPA, DHA, soybean-derived phospholipids, milk-derived phospholipids, The RAL fluids may be potassium phosphate, potassium carbonate, potassium chloride, sodium chloride, calcium lactate, calcium gluconate, calcium pantothenate, casein calcium, magnesium chloride, ferrous sulfate, sodium bicarbonate, but are not particularly limited by each example .

As long as the testosterone 5-alpha reductase inhibiting activity of the composition is maintained, the saccharide, the protein, the lipid, the vitamins and the minerals may include other components, and the content of each component may be testosterone Is not limited as long as the 5-alpha reductase inhibitory activity is maintained, and preferably 0.1 to 15% by weight, preferably 0.5 to 10% by weight relative to the total composition.

The composition for inhibiting testosterone 5-alpha reductase may further contain, in addition to the above-mentioned active ingredients, a compound for the purpose of inhibiting testosterone 5-alpha reductase, for the purpose of maintaining the effect of the present invention, An additive, preferably a substance having an inhibitory activity against a testosterone 5-alpha reductase, and the additional ingredient or additive can be provided so as not to be disturbed by other constituents of the composition.

The testosterone 5-alpha reductase is a biocatalyst that is involved in the conversion of testosterone, which is a male hormone biosynthesized in a testis, into dihydrotestosterone, which exists mainly in the male hormone reactive tissues such as sebaceous gland, hair follicle or prostate. Thus, in the case of inhibiting the action of the testosterone 5-alpha reductase to produce the dihydrootestosterone, that is, inhibiting the production of dihydrootestosterone in the tissue, the hair loss, especially male pattern hair loss, enlargement of the prostate gland or acne and seborrheic dermatitis Prevention, or amelioration of < / RTI >

Therefore, the composition for inhibiting testosterone 5-alpha reductase or the active ingredient of the composition may be an oral composition or an external composition for the treatment, improvement, alleviation or prevention of the hair loss, especially male pattern hair loss, enlargement of the prostate gland, acne or seborrheic dermatitis, For example, as an active ingredient of a pharmaceutical composition, a health functional food composition or a cosmetic composition.

The present invention also relates to a method for the treatment or prophylaxis of a male hormone dependent disease comprising at least one selected from the group consisting of plant extracts, specifically horseradish extract, And to a pharmaceutical composition for prevention.

Since each of the above-mentioned plant extracts, specifically horseradish extract, manganese extract, mulberry tree extract, saphenous extract, lotus extract, or squalane extract can inhibit the activity of testosterone 5-alpha reductase even when used alone, Can be used as an active ingredient.

Further, it has been confirmed that the plant extract used as the active ingredient has a half-effective effect or an ineffective increase in the efficacy depending on the combination thereof, while the specific combination exhibits a remarkably excellent effect, that is, Or a mixture of plant extracts of the active ingredient.

Specifically, in the case of horseradish peroxidase, a significant increase of 68.67% was observed when the extract was used in combination with other extracts, and when the extract was used in combination with horseradish extract or mulberry extract, in particular, mulberry extract 98.81%, and the acid mulberry extract had a remarkable effect when mixed with a manganese extract or a softening extract of softening, preferably a manganese extract, In case of using the extracts of Hornbeam and Softener, there was a remarkable increase in the effect. In the case of the extract, the other extracts did not produce a synergistic effect. However, when they were mixed with the muniqua extract alone, .

In this regard, the active ingredient may be, for example, a horseradish extract and a manganese extract, a manganese extract and an acid mulberry extract, a saponin extract, a softened extract or a squirrel extract, and a mulberry extract.

The male hormone-dependent disease may be any one selected from the group consisting of alopecia, acne, seborrheic dermatitis, and enlarged prostate.

The male hormone-dependent disease is due to the production of excessive dihydrotestosterone, which can induce the alleviation, treatment, improvement or prevention of the symptoms through inhibition of testosterone 5-alpha reductase.

Therefore, the plant extract having the inhibitory effect of the testosterone 5-alpha reductase can be used to inhibit or alleviate male hormone-dependent diseases or to treat or prevent male hormone-dependent diseases.

The pharmaceutical composition for treating or preventing a male hormone dependent disease according to the present invention comprises at least one member selected from the group consisting of the above-mentioned Crataegus extract, Maquis extract, Mulberry leaf extract, Safflower extract, Soft extract, But it is not limited thereto.

The pharmaceutical composition for treating or preventing a male hormone-dependent disease comprising at least one member selected from the group consisting of horseradish extract, mahwang extract, mulberry extract, saphenous extract, soft extract, Lt; / RTI > The animal is a group of organisms corresponding to plants. It mainly consumes organic matter as nutrients, and differentiates digestive organs, excretory or respiratory organs. Preferably, it is a mammal, more preferably a human.

Wherein at least one plant extract selected from the group consisting of plant extracts, specifically horseradish extract, manganese extract, acid mulberry extract, saponin extract, soft extract, and squalane extract is administered alone in a pharmaceutical composition for treating or preventing male hormone- , And may further include other pharmacologically acceptable carriers, excipients, diluents or subcomponents.

More specifically, a composition comprising at least one selected from the group consisting of the above plant extracts, specifically horseradish extract, magpie extract, acid mulberry extract, saponin extract, soft extract and squalene extract may be used as a medicine, When it is used for pharmaceutical use, at least one selected from the group consisting of the above-mentioned horseradish extract, manganese extract, acid mulberry extract, saponin extract, softened extract and squalane extract may be administered by a conventional method to a pharmaceutically acceptable carrier or excipient Or diluted with a diluent.

In this case, the content of at least one selected from the group consisting of horseradish extract, magpie extract, acid mulberry extract, acid extract, 1% by weight to 50% by weight, but the present invention is not limited thereto. Depending on the use of the composition and the method of using the composition, the content of the compound may be appropriately adjusted in a desired amount.

Examples of the pharmaceutically acceptable carrier, excipient or diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, propylhydroxybenzoate, talc, magnesium stearate and mineral oil , Dextrin, calcium carbonate, propylene glycol, liquid paraffin, and physiological saline. However, the present invention is not limited thereto, and any conventional carrier, excipient or diluent may be used. In addition, the pharmaceutical composition may further comprise at least one selected from the group consisting of conventional fillers, extenders, binders, disintegrants, anticoagulants, lubricants, humectants, pH adjusters, nutrients, vitamins, electrolytes, alginic acid and its salts, pectic acid and its salts, , Fragrances, emulsifiers, preservatives, and the like. The above components may be added to at least one selected from the group consisting of the active ingredients of the above-mentioned horseshoe crab, Maquina extract, mulberry extract, saponin extract, softener extract and squalane extract, independently or in combination.

In addition, the composition of the present invention may further comprise, in addition to the effective ingredient, a substance recognized as having a therapeutic or preventive effect on a known male hormone-dependent disease, for example, a substance recognized as a testosterone 5-alpha reductase inhibitory effect .

When the composition is used as a medicament, the administration method can be oral or parenteral. For example, it can be administered through various routes including oral, transdermal, subcutaneous, intravenous, or muscular.

In addition, the formulations of the compositions may vary depending on the method of use and may be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal .

In general, solid dosage forms for oral administration include tablets, pills, soft or hard capsules, pills, powders and granules, which may contain one or more Excipients such as starch, calcium carbonate, sucrose or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.

Liquid preparations for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, Sweeteners, fragrances, preservatives, and the like.

Forms for parenteral administration include creams, looses, ONITMENTS, PLASTERS, LIQUIDS AND SOULTIONS, AEROSOLS, FRUIDEXTRACTS, (ELIXIR), INFUSIONS, SACHET, PATCH or INJECTIONS.

Furthermore, the compositions of the present invention may be formulated using any suitable method known in the art or using methods disclosed in Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA .

The dosage of the composition can be determined in consideration of the administration method, the age, sex, the severity of the patient, the condition of the patient, the degree of absorption of the active ingredient in the body, the inactivation rate and the drug to be used together. Kg body weight to 500 mg / kg body weight, 0.1 mg / kg body weight to 400 mg / kg body weight or 1 mg / kg body weight to 300 mg / kg body weight, And may be administered once or several times in divided doses. The dose is not intended to limit the scope of the invention in any way.

The present invention may also be a food composition for improving or preventing enlargement of the prostate gland, comprising at least one member selected from the group consisting of horseradish extract, mahwang extract, mulberry extract, saponin extract, lotus extract, and extract extract. The food composition may be, for example, a health functional food composition for improving or preventing enlargement of the prostate gland.

As used herein, the term " food " means a natural product or a processed product containing one or more nutrients, preferably a state of being able to be eaten directly through a certain degree of processing, Food, beverage, food additive, and beverage additive.

The food of the present invention can be, for example, various foods, drinks, gum, tea, vitamin complex, health functional food, and the like. More specifically, the food of the present invention can be used as a nutritive food (e.g., crude oil, spirit, baby food, etc.), meat products, fish meat products, tofu, jelly, noodles (Fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various kinds of kimchi, pickles, etc.), and other processed foods (eg, soy sauce, soybean paste, But are not limited to, beverages (e.g., fruit, vegetable beverages, beverages, fermented beverages, lactic acid bacteria, etc.), natural seasonings (e.g. The food, the health functional food, the beverage, the food additive and the beverage additive can be produced by a usual production method.

In the present invention, the health functional food refers to a food group imparted with added value to function or express the function of the food by physical, biochemical, biotechnological techniques, etc., or to control the biological defense rhythm of the food composition, Means a food which is processed and designed so that the body control function related to restoration and the like is sufficiently expressed to the living body.

The health functional food may include food-acceptable food supplementary additives, and may further include suitable carriers, excipients and diluents conventionally used in the production of health functional foods.

In the present invention, beverage is a generic term for drinking or enjoying a taste, and is intended to include a health functional beverage. The beverage is not particularly limited to the ingredients other than the above-mentioned plant extract as an active ingredient as an essential ingredient at the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages .

Examples of such natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and Xylitol, sorbitol, and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate may be generally about 1 to 20 g, preferably 5 to 12 g per 100 ml of the food composition of the present invention. In addition, the composition of the present invention can be used for the production of natural fruit juice, fruit juice drink, Can also be added.

In addition to the above, the food composition of the present invention can be used as a flavoring agent such as a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, Salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. These components can be used independently or in combination. The proportion of such additives is not critical, but may be selected in the range of 0 to 20 parts by weight per 100 parts by weight of the plant composition for improving or preventing enlargement of the prostate gland according to the present invention.

In the present invention, the health functional beverage includes a beverage group to which added value is imparted so that the function of the beverage functions to a specific purpose using physical, biochemical, biotechnological techniques, etc., Means a beverage which is processed by being designed so that the body control function related to recovery and the like is sufficiently expressed to a living body.

The health functional beverage is not particularly limited as long as it contains a plant composition for improving or preventing the enlargement of the prostate gland according to the present invention as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates, .

Examples of such natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and xylitol , Sorbitol, and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention.

In addition, in the food composition for the purpose of preventing or improving the enlargement of the prostate gland, the amount of the plant extract as the active ingredient may be 0.01 to 15% by weight of the total food, 0.02 g to 5 g, preferably 0.3 g to 1 g, based on the total weight of the composition.

The present invention also provides a cosmetic composition for improving or preventing depilation, comprising at least one selected from the group consisting of the above-described horseradish extract, mahwang extract, acid mulberry extract, sapurice extract, soft extract, and insect extract.

At least one selected from the group consisting of horseradish extract, mahwang extract, mulberry extract, saphenous extract, soft extract and squalene extract is derived from a natural substance used for edible purposes, so that side effects are not a problem, and testosterone 5-alpha reduction A cosmetic composition for improving or preventing hair loss comprising at least one member selected from the group consisting of the above-described horseradish extract, manganese extract, acid mulberry extract, saponin extract, soft extract, Can be usefully used for prevention or improvement of hair loss.

The cosmetic composition for improving or preventing hair loss may be applied to hair and / or scalp or applied to skin, for example, a cosmetic composition for hair or a hair cosmetic composition.

The above-mentioned hair cosmetic composition may contain other components added to a conventional hair growth promoting agent such as pepper tincture, tocopheryl acetate and benzyl nicotinate for promoting blood circulation, cicin extract for hair follicle stimulation and cellular activity, Other effects such as hinokitiol, nicotinic acid amide, and l-menthol can be used together with pyrrothonolamine and salicylic acid for sterilization or keratolysis, and other moisturizers.

When the cosmetic composition is a hair cosmetic composition, the hair conditioner, hair tonic, hair cream, hair lotion, hair face, hair gel, hair pack, hair massager, hair liquid, hair spray, hair mousse, non- aerosol mousse, non- , Aerosol mousse, aerosol spray, emulsion, decolorant, aqueous dispersion, powder or oil.

The composition of each of the above-mentioned formulations may contain various kinds of bases and additives necessary for formulation of the formulation, and the kind and amount of these ingredients can be easily selected by those skilled in the art to the extent that the effect of the above- have.

When the formulation of the hair cosmetic composition is a paste, a cream or a gel, it may further contain an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, .

If the formulation of the hair cosmetic composition is a powder or a spray, it may further comprise lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder, especially if the formulation is a spray, additionally chlorofluor Propellants such as hydrocarbons, propane, butane or dimethyl ether.

When the formulation of the hair cosmetic composition is a solution or emulsion, it may contain a solvent, a solubilizing agent or an emulsifying agent, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan, and the like.

When the formulation of the hair cosmetic composition is a suspension, a liquid diluent such as water, ethanol, or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, and the like.

The present invention also provides a cosmetic composition for improving or preventing acne or seborrheic dermatitis comprising at least one selected from the group consisting of horseradish extract, corn oil extract, mulberry extract, saponin extract, soft extract, have.

The cosmetic composition may be used as a cosmetic composition, makeup cosmetic, body cosmetic, hair cosmetic, scalp cosmetic or cosmetic cosmetic.

Examples of the cosmetic cosmetic include a cream, a lotion, a pack, a massage cream, and a milky lotion. Examples of the cosmetic cosmetic include a foundation, a makeup base, a lipstick, an eye shadow, an eyeliner, a mascara, an eyebrow pencil, Examples of the cosmetic material include soap, liquid cleansing agent, bathing agent, sunscreen cream, and sun oil. Examples of the cosmetic for hair include shampoo, rinse, hair treatment, hair mousse, hair liquid, pomade, hair color, hair bleach Examples of the cosmetic composition for scalp include hair tonic or scarf treatment, and examples of the cosmetic composition for shaving include aftershave lotion or shaving cream. Examples of the oral cosmetic composition include Toothpaste or mouth washer.

The cosmetic composition may contain, in addition to the active ingredient, a component incorporated in the cosmetic composition, for example, a moisturizer, an ultraviolet absorber, a vitamin, an animal or plant extract, a digestive agent, a whitening agent, a vasodilator, Hormones and the like may be further added. In addition, the cosmetic composition may further include a medicament or a mechanism necessary for infiltrating or transferring the active ingredient into the dermal tissue.

The formulation of the cosmetic composition may take any appropriate form depending on the intended use and the properties of the cosmetic composition. Examples of the formulation include an aqueous solution, a solubilization system, an emulsion system, an emulsion system, a gel system, a paste system, an ointment system, A two-layer system or a water-oil-powder three-layer system. Examples of the formulations are merely illustrative, and the formulations and forms of the cosmetic composition of the present invention are not limited by the above examples.

The active ingredient may be contained in an amount of 0.001 to 50% by weight, and preferably 0.01 to 20% by weight, based on the total weight of the cosmetic composition, but the content is preferably such that the content of components other than the active ingredient contained in the formulation or cosmetic composition , And the content of the active ingredient contained in the present invention is not limited by the above content.

The cosmetic composition of the present invention may contain, in addition to the above plant extracts as an active ingredient, a compound having an anti-acne effect or a sebum-reducing ingredient, for example, a substance having a testosterone 5-alpha reductase inhibiting effect or an excipient , Diluent, and the like may be further included.

For example, the cosmetic composition may further contain a perfume, a pigment, a bactericide, an antioxidant, an antiseptic, a moisturizer, a thickening agent, an inorganic salt, or a synthetic polymer material to improve physical properties. An organic pigment, an organic pigment, an ultraviolet absorber, a pH adjuster, an alcohol, a blood circulation accelerator, a cold agent, a limiting agent, or purified water may be used as a blending component that may be added.

The cosmetic composition may further include at least one selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.

The components other than the above-mentioned effective components may be added within the range that does not impair the objects and effects of the present invention.

The cosmetic composition may be in the form of a solution, an emulsion, a viscous mixture or the like, and may be in the form of a liquid, a cream, a lotion, a pack, a foundation, a lotion, a serum, Lt; / RTI >

More particularly, the cosmetic composition of the present invention can be used as a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutritional cream, a moisturizing cream, a hand cream, a foundation, , Packs, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions and body cleansers.

For example, when the formulation of the present invention is a paste, a cream or a gel, an animal fiber, a plant fiber, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc or zinc oxide Can be used.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as the carrier component. In particular, when the formulation of the present invention is a spray, Propane / butane, or dimethyl ether. ≪ RTI ID = 0.0 >

When the formulation of the present invention is a solution or an emulsion, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, -Butyl glycol oil, glycerol aliphatic esters, polyethylene glycols or fatty acid esters of sorbitan.

When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolenic derivatives or ethoxylated glycerol fatty acid esters.

The active ingredients of the present invention, which are the natural plant extracts, are different from the compounds used as testosterone 5-alpha reductase inhibitors in that they have side effects or safety problems, such as horseradish extract, magpie extract, acid mulberry extract, The testosterone 5-alpha reductase can be effectively inhibited, and synergistic effects can be remarkably exerted by the mixed use. Therefore, it is possible to provide a test compound for the testosterone 5-alpha reductase, a male hormone-dependent disease , Can be used for the treatment, improvement or prevention of benign prostatic hyperplasia and can also be used for the manufacture of cosmetics for the prevention or amelioration of male pattern baldness, acne or seborrheic dermatitis, so that the present invention relates to the treatment of diseases and conditions associated with testosterone 5-alpha reductase , Improvement, mitigation or prevention That can be widely used in the fields of medical industry, food industry and cosmetics industry.

Hereinafter, preferred embodiments of the present invention will be described. However, the following examples are only a preferred embodiment of the present invention, and the present invention is not limited by the following examples.

< Example  1> Preparation of Plant Extract

Dried 100% of the top part of the bark of horsehair, horse bark, bark of mountain mulberry, bark of bark of mountain mulberry, bark of bark of sycamore, flower of soften which was purchased on Chinese medicine in Kangwon-do, L was added and the mixture was refluxed for 3 hours at 100 ° C using a reaction tank (MS-CM709).

Each of the extracted extracts was concentrated under reduced pressure using a rotary evaporator (Eyela N-1000, Japan). The concentrated extract of the concentrated extract was concentrated to obtain 11.6 g of each of the extracts of Crataegus nipponensis, 15.4 g of Maju extract, 10.5 g of mung bean extract, 15 g of the extract of Sophora japonica, 16 g of the softened extract and 9.7 g of the extract extract .

The samples were stored at -20 &lt; 0 &gt; C until used in the experiment.

< Example  2> Testosterone 5-alpha Reductase Inhibitory Effect

In order to confirm the testosterone 5-alpha reductase inhibitory effect of the extract, testosterone 5-alpha reductase was prepared as follows.

Specifically, the liver of rat fasted for 24 hours was perfused with ice-cold Krebs-Ringer's phosphate buffer (pH 7.2) to remove blood. To this was added ice-cold 0.01 M Tris-HCl buffer (pH 7.2) in an amount 1.4 times the above-mentioned buffer, homogenized, and centrifuged at 3000 rpm and 4 ° C for 10 minutes. After the centrifugation, the upper layer was separated, and the separated upper layer was centrifuged again for 10 minutes at 7,000 rpm and 4 ° C. After the centrifugation, the upper layer was separated, and the separated supernatant was centrifuged once more at 10,000 rpm and 4 ° C for 10 minutes, and then the supernatant was separated and used as an enzyme solution. The enzyme solution was cryopreserved at -70 ° C until use in the experiment.

The testosterone 5-alpha reductase inhibitory effect of the above extract was carried out using the obtained enzyme solution as follows.

First, 50 μl of testosterone (500 μg / ml), 50 μl of the test solution in which each of the extract samples prepared in Example 1 were dissolved, and 160 μl of the testosterone 5-alpha reductase enzyme solution prepared above were mixed and NADPH (0.77 Mg / ml) and 400 쨉 l of 2 mM dithiothreitol were added to the reaction solution, followed by incubation at 37 째 C for 30 minutes.

After the reaction, 820 μl of a solution of internal standard (p-hydroxybenzoic acid n-hexyl ester, 0.01 mg / ml) in dichloromethane was added to stop the reaction.

After that, vortexing was performed, and the upper and lower portions were thoroughly mixed, followed by centrifugation at 3,000 rpm for 10 minutes to remove the upper layer. Thereafter, the dichloromethane layer was flushed with nitrogen, 500 μl of methanol was added thereto, and the amount of testosterone remaining was determined by high performance liquid chromatography (HPLC).

Thermo Hypersil Gold C18 (150 x 4.6 mm) was used as a column for the measurement of the high performance liquid chromatography. The mobile phase was a mixture of methanol and water in a ratio of 65:35. The flow rate was 1.0 ml / min, The column temperature was 40 캜, the injection amount was 20 ㎕, and the detection wavelength was 254 nm.

The high-performance liquid chromatography used the internal standard method and the content of testosterone was calculated by the peak-area ratio (testosterone / internal standard). The inhibition rate of testosterone 5-alpha reductase activity of each of the extracts was calculated by the following formula 1 using the content of testosterone calculated by the above-mentioned ratio of pork-area. As a positive control for comparing the effects of the plant extracts, commercially available testosterone 5-alpha reductase inhibitors such as finasteride and ethinylestradiol were used.

[Equation 1]

Suppression rate (%) = 100 x {(A-B) / (C-B)}

In the above equation (1), A represents the peak area ratio when the plant extract or the positive control of Example 1 was added for 30 minutes, and B represents the amount of the enzyme solution prepared in the above Example , And C represents the peak area ratio when the reaction is performed for 0 min, that is, when the reaction is not proceeded by adding dichloromethane to which an internal standard is added before addition of NADPH.

The concentrations (EC 30%, 30% of the effect concentration) of 50% inhibition rate (IC ₅₀ ) and inhibitory effect of 30% of each extract were determined on the basis of the results calculated by the above formula, Respectively.

sample Concentration (ug / ml) Inhibition rate (%) IC ₅₀ (ug / ml) Ethinyl estradiol
(Ethinylestradiol) 666.67 56.58 560.94 333.33 36.07 66.67 5.04 Finasteride
(Finasteride) 66.67 85.28 39.08 33.33 41.81 6.67 9.56 Horseradish extract 666.67 59.45 600.39 333.33 20.22 66.67 17.63 Mahwang extract 666.67 62.98 554.22 333.33 23.81 66.67 7 Mulberry extract 666.67 96.87 160.10 333.33 80.66 66.67 17.69 Sanchene extract 666.67 52.95 613.05 333.33 31.58 66.67 7.96 Softener extract 666.67 56.36 604.04 333.33 24.99 66.67 6.82 Excreta extract 666.67 81.34 229.42 333.33 71.75 66.67 4.08

Horseradish
(占 퐂 / ml) Mahwang
(占 퐂 / ml) Mountain mulberry
(占 퐂 / ml) Sancheong
(占 퐂 / ml) Softening example
(占 퐂 / ml) Recruitment
(占 퐂 / ml) Inhibition rate
(%) 321.45 342.13 90.74 344.59 363.07 129.66 30

As shown in the above Tables 1 and 2, the EC30 concentrations of the plant extracts inhibiting the activity of testosterone 5-alpha reductase by 30% were 321.45 占 퐂 / ㎖, 342.13 占 퐂 / Mulberry extract was 90.74 占 퐂 / ml, the extract of cormorant was 344.59 占 퐂 / ml, the extract of softened case was 363.07 占 퐂 / ml and the extract was 129.66 占 퐂 / ml. From the above results, it was confirmed that the acid mulberry extract and the squirrels extract in the above extracts were more effective than the ethinyl estradiol.

< Example  3> Each plant Between extracts  Identify synergy

The synergistic effect of the mixed use was confirmed by mixing each of the six plant extracts having the testosterone 5-alpha reductase inhibitory activity in Example 2 based on the EC30 concentration. 1/3, 1/4, 1/5 and 1/6 of the EC30 content of each plant extract was mixed according to the number of the plant extracts to be mixed as shown in Table 3 below to obtain the total volume 50 [mu] l, and testosterone 5-alpha reductase inhibitory activity was confirmed by the same method as in Example 2 for the prepared mixed sample, and the results are shown in Table 3 below. The synergistic effects shown in Table 3 were obtained by the following formula 2. &lt; tb &gt; &lt; TABLE &gt;

[Equation 2]

Synergistic potency increase rate (%) = {(inhibition rate% -30%) / 30%} × 100

N0 Horseradish
extract
(占 퐂 / ml) Mahwang
extract
(占 퐂 / ml) Mountain mulberry
extract
(占 퐂 / ml) Sancheong
extract
(占 퐂 / ml) Softening example
extract
(占 퐂 / ml) Recruitment
extract
(占 퐂 / ml) Inhibition rate
(%) Synergistic efficacy growth rate (%) One 1/2 1/2 50.60 68.67 2 1/2 1/2 39.50 31.66 3 1/2 1/2 42.08 40.25 4 1/2 1/2 37.58 25.27 5 1/2 1/2 20.14 - 6 1/2 1/2 59.64 98.81 7 1/2 1/2 33.33 11.11 8 1/2 1/2 37.07 23.56 9 1/2 1/2 - - 10 1/2 1/2 - - 11 1/2 1/2 50.85 69.49 12 1/2 1/2 40.46 34.87 13 1/2 1/2 40.31 34.38 14 1/2 1/2 4.17 - 15 1/2 1/2 - - 16 1/3 1/3 1/3 17.17 - 17 1/3 1/3 1/3 - - 18 1/3 1/3 1/3 2.56 - 19 1/3 1/3 1/3 31.03 3.45 20 1/3 1/3 1/3 11.39 - 21 1/3 1/3 1/3 21.39 - 22 1/3 1/3 1/3 - - 23 1/3 1/3 1/3 38.81 29.35 24 1/3 1/3 1/3 20.63 - 25 1/3 1/3 1/3 17.89 - 26 1/4 1/4 1/4 1/4 30.25 - 27 1/4 1/4 1/4 1/4 32.92 9.75 28 1/4 1/4 1/4 1/4 - - 29 1/4 1/4 1/4 1/4 11.16 - 30 1/4 1/4 1/4 1/4 6.27 - 31 1/4 1/4 1/4 1/4 6.92 - 32 1/5 1/5 1/5 1/5 1/5 - - 33 1/5 1/5 1/5 1/5 1/5 26.79 - 34 1/5 1/5 1/5 1/5 1/5 23.49 - 35 1/6 1/6 1/6 1/6 1/6 1/6 35.73 19.10

As shown in Table 3, the synergistic effect was found to be 19.10% in the case of the mixture of all six kinds, but the synergistic effect was different depending on the type of the extract to be mixed. In particular, in the case of horseradish perilla extract, 68.67% of the extract was used in combination with the extract of mahwang, and 68.67% of the extract was used in the case of the extract of mahwah, The results showed that the acid mulberry extract had a remarkable effect of 98.49% when used in combination with manganese extract or softened extract, specifically softened extract, 69.49% There was a remarkable increase in the effect of the extract of Sanskrit extract when used in combination with horseradish extract and softener extract. In addition, synergistic effect did not occur in other extracts in the excreted extract, but it was confirmed that the effect was increased when the extract was mixed with the mulberry extract alone.

From these results, it was confirmed that the inhibitory effect of extracts capable of inhibiting testosterone 5-alpha reductase was increased or decreased according to the combination thereof.

Claims (7)

A pharmaceutical composition for the treatment or prophylaxis of male hormone-dependent diseases, which is selected from the group consisting of alopecia, acne, seborrheic dermatitis, and enlarged prostate comprising the extract of Ephedra sinica and Morus bombycis as an active ingredient. The method according to claim 1,
The pharmaceutical composition for the treatment or prevention of the male hormone-dependent disease includes a mixture of Ephedra sinica extract and Morus bombycis extract in an amount of 1: 1, A pharmaceutical composition for treating or preventing a hormone-dependent disease. A composition for improving or preventing prostatic hyperplasia comprising an extract of Ephedra sinica and an extract of Morus bombycis as an active ingredient. A cosmetic composition for improving or preventing alopecia comprising an extract of Ephedra sinica and an extract of Morus bombycis as an active ingredient. A cosmetic composition for improving or preventing acne or seborrheic dermatitis comprising Ephedra sinica extract and Morus bombycis extract as an active ingredient. delete delete